Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 23Ovarian Neoplasms 20Triple Negative Breast Neoplasms 12Neoplasms 9Neoplasm Metastasis 9Fallopian Tube Neoplasms 9Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Glioblastoma 5Astrocytoma 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Gliosarcoma 4Colonic Neoplasms 4Brain Neoplasms 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Melanoma 3Lymphoma 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Thrombocythemia, Essential 2Testicular Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Geriatric Assessment 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Neoplasm × veliparib × Clear all
NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡